288 related articles for article (PubMed ID: 37551929)
21. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
22. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
23. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.
Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T
PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953
[TBL] [Abstract][Full Text] [Related]
24. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M
ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608
[TBL] [Abstract][Full Text] [Related]
26. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacological therapy of heart failure with reduced ejection fraction].
Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
[TBL] [Abstract][Full Text] [Related]
28. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
30. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
Nochioka K; Sakata Y; Shimokawa H
Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
[TBL] [Abstract][Full Text] [Related]
31. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
32. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
33. ARNI in cardiovascular disease: current evidence and future perspectives.
Kuchulakanti PK
Future Cardiol; 2020 Sep; 16(5):505-515. PubMed ID: 32319309
[TBL] [Abstract][Full Text] [Related]
34. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction.
Böhm M; Tschöpe C; Wirtz JH; Lokies J; Turgonyi E; Bramlage P; Lins K; Strunz AM; Tebbe U
Clin Cardiol; 2015 Apr; 38(4):200-7. PubMed ID: 25733185
[TBL] [Abstract][Full Text] [Related]
35. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
36. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
[TBL] [Abstract][Full Text] [Related]
37. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
39. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
[TBL] [Abstract][Full Text] [Related]
40. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
